Risk assessment industry driven approach in occupational health and safety.

Introduction: Risk assessment and management in companies plays a significant role in the prevention section of any field. In the field of Occupational Health and Safety (OHS), its inconsistent or incorrect application has a direct impact on the life and health of employees. In some companies, even today, it is not properly implemented and adequate procedures and methods are not used. The article discusses the development of a step-by-step procedure for risk assessment in industrial environments in the area of OHS. Methods: Main parts of the model and its steps present the partial results of a survey conducted on a sample of 500 small and micro enterprises in the field of risk assessment and the systematic procedure developed following the main survey results. The survey covered only enterprises located in the construction, manufacturing, transport and storage and agriculture, forestry and fishing sectors, which is also a significant statistical feature. Within the structure of respondents, statistical features such as: size of enterprise, sector, region by work are identified. Only enterprises with size by number of employees - micro enterprises from 1 to 9 employees and small enterprises from 10 to 49 employees - were included for the survey. Results: New elements of the methods were integrated into the developed systematic procedure, which was subsequently validated in 7 plants of the one company on the same position. The application of the developed model was verified by an expert group consisting of 7 members, an odd number, and the developed checklists and risk register were applied. On the basis of the verification, the model, checklist and risk register were corrected. In addition, the scoring method and the risk matrix were also used, but they did not contain new elements. Discusion: The procedure is still in use today and employees have been trained to use it. On the basis of the developed methodology and the Checklist, the procedure has been transposed into the European OiRA tool and can be used by companies throughout the European Union.

An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study.

PURPOSE: A national primary and secondary healthcare-level study in the Czech Republic has not yet been conducted to evaluate the prevalence of migraine. We analyzed the current treatment patterns (acute and prophylactic) in migraine patients and the number of migraine patients potentially eligible for treatment with recent calcitonin gene-related peptide (CGRP) pathway-targeted therapies. METHODS: This retrospective study utilized the Ministry of the Interior Health Insurance Fund claims database of the Czech Republic wherein every citizen is insured. Migraine patients with or without aura, and potentially on triptan therapy were included in this study (index years 2012-2016). The prevalence approach included all patients (new and old) present in each index year. Prophylactic therapies were followed f0or three and seven years prior to the index year, including the index year, until 2010. The incidence approach included all patients first diagnosed in each index year. Prophylactic therapies were followed for the next three years, including the index year, until 2017 following incidence approach. The primary endpoint of this study was to determine the rate of migraine prevalence and diagnosis for each index year during the period 2012-2016. The study also evaluated prophylactic and acute treatment patterns and comorbidities among patients in 2016. RESULTS: The rate of migraine prevalence was 1% and the rate of diagnosis was 0.2-0.4%. By prevalence approach, approximately 39% of the patients were on prophylactics, and 11.2% and 21.6% of the patient population had two prior treatment failures (three- and seven-year recall period, respectively). Antiepileptics (26%) and beta blockers (15.8%) were the most prescribed prophylactics, and sumatriptan was the predominant triptan used (12%) for acute treatment. CONCLUSION: Taking into account the number of inhabitants in the Czech Republic (10.7 million), there could be up to 23,000 adult patients eligible for novel CGRP therapies.